RecruitingPhase 2NCT07266441

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Sponsor

Janssen Research & Development, LLC

Enrollment

157 participants

Start Date

Feb 8, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called JNJ-79635322 for people with multiple myeloma — a cancer of plasma cells in the bone marrow — whose disease has come back or stopped responding to previous treatments. **You may be eligible if...** - You have been diagnosed with multiple myeloma - Your cancer is measurable on tests at the time of screening - You have received at least 3 prior lines of treatment, including specific drug types: a proteasome inhibitor (e.g., bortezomib), an immunomodulatory drug (e.g., lenalidomide), and an anti-CD38 antibody (e.g., daratumumab) - Your myeloma is progressing or did not respond to your most recent treatment - You are in reasonably good physical health (ECOG performance status 0–2) **You may NOT be eligible if...** - You have had a major surgery within 2 weeks before starting the study - Your myeloma has spread to the brain or nervous system - You have another active cancer that could interfere with the study - You have a known allergy to the study drug's ingredients Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJNJ-79635322

JNJ-79635322 will be administered as an injection under the skin.

Locations(37)

O Neal Comprehensive Cancer Center at UAB

Birmingham, Alabama, United States

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States

City of Hope

Duarte, California, United States

City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, United States

Cancer and Blood Specialty Clinic

Los Alamitos, California, United States

University of California San Francisco

San Francisco, California, United States

Rocky Mountain Cancer Centers

Aurora, Colorado, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Cancer Specialists of North Florida

Jacksonville, Florida, United States

Emory University

Atlanta, Georgia, United States

Northside Hospital Cancer Institute

Atlanta, Georgia, United States

Cancer Care Specialists of Central Illinois

O'Fallon, Illinois, United States

University of Iowa

Iowa City, Iowa, United States

Mission Cancer Blood

Waukee, Iowa, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Rutgers Cancer Institute

New Brunswick, New Jersey, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Cleveland Clinic Foundtation

Cleveland, Ohio, United States

Oncology Associates of Oregon PC Willamette Valley Cancer Institute

Eugene, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Texas Oncology

Austin, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

Oncology Consultants Texas

Houston, Texas, United States

Texas Oncology - Northeast

Tyler, Texas, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Virginia Oncology Associates

Norfolk, Virginia, United States

NorthWest Medical Specialties, PLLC

Tacoma, Washington, United States

Ha'Emek Medical Center

Afula, Israel

Samson Assuta Ashdod University Hospital

Ashdod, Israel

Hillel Yaffe Medical Center

Hadera, Israel

Hadassah Medical Center

Jerusalem, Israel

Rabin Medical Center

Petah Tikva, Israel

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

National Hospital Organization Shibukawa Medical Center

Gunma, Japan

National Hospital Organization Okayama Medical Center

Okayama, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07266441

Related Trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

NCT0703051712 locations

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

NCT0676848914 locations

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT0714985717 locations

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT0725851143 locations